Both cyclosporine and tacrolimus were produced by multidisciplinary research teams working at pharmaceutical companies and looking for immunosuppressants having a gentle profile of cytotoxic undesireable effects [39]

Both cyclosporine and tacrolimus were produced by multidisciplinary research teams working at pharmaceutical companies and looking for immunosuppressants having a gentle profile of cytotoxic undesireable effects [39]. the post-operative tension continues to be overcome. The predominant defect induced by CNI

The overall response rate (ORR), progression-free survival (PFS) and overall survival (OS) times favor 1st (gefitinib, erlotinib) and 2nd (afatinib) generation EGFR TKIs when compared to chemotherapy [1]

The overall response rate (ORR), progression-free survival (PFS) and overall survival (OS) times favor 1st (gefitinib, erlotinib) and 2nd (afatinib) generation EGFR TKIs when compared to chemotherapy [1]. in wild-type cancers treated with 1st generation EGFR TKIs (p=0.035). Conclusions Concurrent